Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2018-01-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
发行股份及支付现金购买资产暨关联交易报告书摘要
Capital/Financing Update Classification · 95% confidence The document is titled "发行股份及支付现金购买资产暨关联交易报告书" which translates to "Report on Issuance of Shares and Payment of Cash to Purchase Assets and Related Party Transactions." It details a transaction involving issuance of shares and cash payment to acquire 90% equity of a target company, including valuation, pricing, lock-up periods, performance commitments, and related party declarations. The document includes detailed financial and transaction information, legal and regulatory references, and commitments from involved parties. This is a comprehensive report on a major asset acquisition and related party transaction, which fits the category of Capital/Financing Update (CAP) as it involves issuance of shares and cash payment for asset acquisition and related financing activities. It is not an announcement of a report publication, nor a full annual or interim report, nor a proxy or voting result. Therefore, the appropriate classification is CAP with high confidence.
2018-01-28 Chinese
关于公司股票复牌的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the resumption of trading (relisting) of the company's stock after a suspension due to a major asset restructuring. It references prior suspension notices and updates on the restructuring process, but does not contain financial statements or detailed financial data. The document length is only 1434 characters, which is quite short and consistent with an announcement rather than a full report. The content focuses on the stock resumption and related procedural updates, not on the actual asset restructuring report or financial results. Therefore, it fits best as a Regulatory Filing (RNS) since it is a regulatory announcement about stock resumption and related disclosures, not a full report or detailed financial document.
2018-01-28 Chinese
关于公司发行股份及支付现金购买资产暨关联交易之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to Quantum Hi-Tech's issuance of shares and cash payment for asset acquisition and related party transactions. It is issued by a financial advisory firm (Guangfa Securities) and includes detailed sections such as transaction overview, asset valuation, issuance of shares, lock-up periods, performance commitments, major asset restructuring, related party transactions, and legal and financial due diligence. The document is comprehensive, lengthy (15,000 characters), and contains detailed financial and legal analysis related to a major asset acquisition and restructuring transaction. This type of document is a standalone audit or advisory report related to a significant corporate transaction, not a full annual or interim report, nor a simple announcement or presentation. It fits the category of an Audit Report / Information (AR) as it provides independent financial advisory opinions, valuation, and compliance analysis for a major asset acquisition and related party transaction.
2018-01-28 Chinese
关于延期召开2018年第一次临时股东大会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the postponement of the 2018 first extraordinary general meeting (临时股东大会) of Quantum Hi-Tech (量子高科). It details the original and new meeting dates, voting times, and reasons for the delay, including a regulatory inquiry from the Shenzhen Stock Exchange. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a formal announcement about a shareholder meeting schedule change. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other more specific categories like AGM Information or Declaration of Voting Results, since it is about postponement rather than the meeting content or voting results.
2018-01-24 Chinese
关于收到深圳证券交易所重组问询函的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Quantum Hi-Tech (China) Biological Co., Ltd. regarding a restructuring inquiry letter received from the Shenzhen Stock Exchange. It references a previously disclosed report titled "Issuance of Shares and Payment of Cash to Purchase Assets and Related Party Transaction Report" and requests further clarifications and supplementary disclosures related to a major asset restructuring transaction. The document is a regulatory inquiry and request for additional information about a restructuring transaction, not the transaction report itself. It is relatively short (3359 characters) and serves as a formal regulatory communication rather than a full financial or restructuring report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2018-01-24 Chinese
关于控股股东部分股份解除质押的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the partial release of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, dates, and related parties. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, which fits the category of Share Issue/Capital Change or Transaction in Own Shares. However, since it concerns the release of pledged shares (a capital structure change related to share pledging), the most appropriate classification is Transaction in Own Shares (POS). The document length is short and it is a formal announcement, not a report or presentation.
2018-01-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.